1. Home
  2. LMRI vs SLDB Comparison

LMRI vs SLDB Comparison

Compare LMRI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumexa Imaging Holdings Inc. Common Stock

LMRI

Lumexa Imaging Holdings Inc. Common Stock

N/A

Current Price

$11.02

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$7.82

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMRI
SLDB
Founded
2018
2013
Country
United States
United States
Employees
4335
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
LMRI
SLDB
Price
$11.02
$7.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$20.75
$16.36
AVG Volume (30 Days)
571.0K
1.6M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.97
EPS
N/A
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
$6.35
N/A
Revenue Next Year
$5.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.45
$3.79
52 Week High
$19.45
$11.45

Technical Indicators

Market Signals
Indicator
LMRI
SLDB
Relative Strength Index (RSI) 54.66 36.26
Support Level $10.21 $6.38
Resistance Level $12.93 $8.12
Average True Range (ATR) 0.74 0.54
MACD -0.18 -0.36
Stochastic Oscillator 30.24 4.12

Price Performance

Historical Comparison
LMRI
SLDB

About LMRI Lumexa Imaging Holdings Inc. Common Stock

Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: